Advertisement

Cytotechnology

, Volume 70, Issue 4, pp 1143–1154 | Cite as

Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells

  • C. Lavanya
  • Manjunatha M. Venkataswamy
  • M. K. Sibin
  • M. M. Srinivas Bharath
  • G. K. Chetan
Article
  • 135 Downloads

Abstract

Increased telomerase activity can be blocked by targeting the hTERT activity at both RNA and catalytic subunits. Various inhibitors had been used to regulate hTERT activity in glioblastoma cell lines and showed promising results. The present study hypothesized that the telomerase specific inhibitor BIBR1532 can effectively down-regulate the telomerase activity in LN18 glioblastoma cell line. LN18 glioblastoma cell line was treated with various concentrations of BIBR1532 at different time intervals. MTT assay was performed to determine cell viability after BIBR1532 treatment. hTERT mRNA and protein expression were determined by qRT-PCR and western blotting, respectively. Flow cytometry and TRAP assay was performed to detect the rate of apoptosis and telomerase activity in treated and control samples. One-way ANOVA was performed to compare the mean values of variables in control and BIBR1532 treated groups. LN18 cells showed a significant dose dependent cytotoxic effect after treatment with BIBR1532. hTERT mRNA expression in cells treated with 25, 100 and 200 μM BIBR1532 treated groups was decreased ~ 21, ~ 61.2, and ~ 77%, respectively (p < 0.05). We also observed that, BIBR1532 treatment reduced the expression of hTERT protein in LN18 cells in a dose dependent manner. The Flow cytometry data showed that, the drug induced significant increase in the total percentage of apoptotic cells with 200 μM concentration of BIBR1532 at all time points. BIBR1532 exhibited potent inhibition of telomerase activity in a dose-dependent manner in LN18 cells. BIBR1532 could induce apoptosis in LN18 cells through the downregulation of telomerase activity at transcriptional and translational level. We conclude that BIBR1532 may be a therapeutic agent to suppress telomerase activity, however, further efforts are necessary in order to explore this therapeutic strategy.

Keywords

hTERT BIBR1532 Glioblastoma Regulation 

Notes

Acknowledgements

Lavanya C was supported by a UGC RGNF-Senior research fellowship (University Grants Commission-Rajiv Gandhi National Fellowship), New Delhi, India. The study was financially supported by DST-SERB (Department of Science & Technology-Science and Engineering research Board), Government of India. We thank Dr. Vijay Kumar Kalia for providing chemicals and reagents.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Supplementary material

10616_2018_205_MOESM1_ESM.docx (11 kb)
Supplementary material 1 (DOCX 11 kb)

References

  1. Artandi SE, DePinho RA (2010) Telomeres and telomerase in cancer. Carcinogenesis 31:9–18CrossRefGoogle Scholar
  2. Arvold ND, Reardon DA (2014) Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 9:357–367Google Scholar
  3. Asai A, Oshima Y, Yamamoto Y, Uochi TA, Kusaka H, Akinaga S, Gryaznov S (2003) A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 63:3931–3939Google Scholar
  4. Bashash D, Ghaffari SH, Zaker F, Hezave K, Kazerani M, Ghavamzadeh A, Vossough P (2012) Direct short-term cytotoxic effects of BIBR 1532 on acute promyelocytic leukemia cells through induction of p21 coupled with downregulation of c-Myc and hTERT transcription. Cancer Investig 30:57–64CrossRefGoogle Scholar
  5. Bashash D, Ghaffari SH, Mirzaee R, Alimoghaddam K, Ghavamzadeh A (2013) Telomerase inhibition by non-nucleosidic compound BIBR1532 causes rapid cell death in pre-B acute lymphoblastic leukemia cells. Leuk Lymphoma 54:561–568CrossRefGoogle Scholar
  6. Blasco MA (2005) Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6:611–622CrossRefGoogle Scholar
  7. Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, Brummendorf TH (2011) Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 39:66–76CrossRefGoogle Scholar
  8. Cerni C (2000) Telomeres, telomerase, and myc. An update. Mutat Res 462:31–47CrossRefGoogle Scholar
  9. Chen Z, Koeneman KS, Corey DR (2003) Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells. Cancer Res 63:5917–5925Google Scholar
  10. Cong YS, Wen J, Bacchetti S (1999) The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8:137–142CrossRefGoogle Scholar
  11. Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425CrossRefGoogle Scholar
  12. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, Bacchetti S (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11:1921–1929Google Scholar
  13. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Schnapp A (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20:6958–6968CrossRefGoogle Scholar
  14. De Cian A, Lacroix L, Douarre C, Temime-Smaali N, Trentesaux C, Riou JF, Mergny JL (2008) Targeting telomeres and telomerase. Biochimie 90:131–155CrossRefGoogle Scholar
  15. El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM (2005) Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 105:1742–1749CrossRefGoogle Scholar
  16. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35:495–516CrossRefGoogle Scholar
  17. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N (2005) Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 305:300–311CrossRefGoogle Scholar
  18. Falchetti ML, Pallini R, Larocca LM, Verna R, D’Ambrosio E (1999) Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 52:234–236CrossRefGoogle Scholar
  19. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21:2683–2710CrossRefGoogle Scholar
  20. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Weinberg RA (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164–1170CrossRefGoogle Scholar
  21. Harley CB, Futcher AB, Greider CW (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345:458–460CrossRefGoogle Scholar
  22. Herbert B, Pitts AE, Baker SI, Hamilton SE, Wright WE, Shay JW, Corey DR (1999) Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 96:14276–14281CrossRefGoogle Scholar
  23. Horikawa I, Cable PL, Afshari C, Barrett JC (1999) Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59:826–830Google Scholar
  24. Komata T, Kanzawa T, Kondo Y, Kondo S (2002) Telomerase as a therapeutic target for malignant gliomas. Oncogene 21:656–663CrossRefGoogle Scholar
  25. Kong W, Lv N, Wysham WZ, Roque DR, Zhang T, Jiao S, Zhou C (2015) Knockdown of hTERT and treatment with BIBR1532 inhibit cell proliferation and invasion in endometrial cancer cells. J Cancer 6:1337–1345CrossRefGoogle Scholar
  26. Kraemer K, Fuessel S, Kotzsch M, Ning S, Schmidt U, Wirth MP, Meye A (2004) Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment. J Urol 172:2023–2028CrossRefGoogle Scholar
  27. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Inoue M (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28:669–677CrossRefGoogle Scholar
  28. Lavanya C, Sibin MK, Srinivas Bharath MM, Manoj MJ, Venkataswamy MM, Bhat DI, Chetan GK (2016) RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology 68:2311–2321CrossRefGoogle Scholar
  29. Lotsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Spiegl-Kreinecker S (2013) Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro Oncol 15:423–432CrossRefGoogle Scholar
  30. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefGoogle Scholar
  31. Lu MH, Liao ZL, Zhao XY, Fan YH, Lin XL, Fang DC, Yang SM (2012) hTERT-based therapy: a universal anticancer approach (review). Oncol Rep 28:1945–1952CrossRefGoogle Scholar
  32. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Bachoo RM (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16:154–163CrossRefGoogle Scholar
  33. Meng E, Taylor B, Ray A, Shevde LA, Rocconi RP (2012) Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cells. Gynecol Oncol 124:598–605CrossRefGoogle Scholar
  34. Mergny JL, Riou JF, Mailliet P, Teulade-Fichou MP, Gilson E (2002) Natural and pharmacological regulation of telomerase. Nucleic Acids Res 30:839–865CrossRefGoogle Scholar
  35. Mueller S, Hartmann U, Mayer F, Balabanov S, Hartmann JT, Brummendorf TH, Bokemeyer C (2007) Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs 25:519–524CrossRefGoogle Scholar
  36. Nijaguna MB, Patil V, Urbach S, Shwetha SD, Sravani K, Hegde AS, Somasundaram K (2015) Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding Protein 1 (IGFBP1) to promote angiogenesis. J Biol Chem 290:23401–23415CrossRefGoogle Scholar
  37. Osterhage JL, Friedman KL (2009) Chromosome end maintenance by telomerase. J Biol Chem 284:16061–16065CrossRefGoogle Scholar
  38. Parsch D, Brassat U, Brummendorf TH, Fellenberg J (2008) Consequences of telomerase inhibition by BIBR1532 on proliferation and chemosensitivity of chondrosarcoma cell lines. Cancer Invest 26:590–596CrossRefGoogle Scholar
  39. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, Schnapp A (2002) Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 277:15566–15572CrossRefGoogle Scholar
  40. Ruden M, Puri N (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39:444–456CrossRefGoogle Scholar
  41. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN (2007) Molecularly targeted therapy for malignant glioma. Cancer 110:13–24CrossRefGoogle Scholar
  42. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, Tsuruo T (2002) Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 1:657–665Google Scholar
  43. Shay JW, Wright WE (2011) Role of telomeres and telomerase in cancer. Semin Cancer Biol 21:349–353CrossRefGoogle Scholar
  44. Shi Y, Sun L, Chen G, Zheng D, Li L, Wei W (2015) A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines. Target Oncol 10:565–573CrossRefGoogle Scholar
  45. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828Google Scholar
  46. Strahl C, Blackburn EH (1996) Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol 16:53–65CrossRefGoogle Scholar
  47. Wai LK (2004) Telomeres, telomerase, and tumorigenesis: a review. Med Gen Med 6:19Google Scholar
  48. Ward RJ, Autexier C (2005) Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 68:779–786Google Scholar
  49. Wojtyla A, Gladych M, Rubis B (2011) Human telomerase activity regulation. Mol Biol Rep 38:3339–3349CrossRefGoogle Scholar
  50. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, Dalla-Favera R (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21:220–224CrossRefGoogle Scholar
  51. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Yu JS (2004) Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23:9392–9400CrossRefGoogle Scholar
  52. Zhang RG, Wang XW, Xie H (2001) Telomerase activity inhibition and apoptosis induction of BEL-7404 human hepatoma cells by antisense oligonucleotides to telomerase RNA component. Shi Yan Sheng Wu Xue Bao 34:213–218Google Scholar
  53. Zhang X, Zhang W, Cao WD, Cheng G, Zhang YQ (2012) Glioblastoma multiforme: molecular characterization and current treatment strategy (review). Exp Ther Med 3:9–14CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  • C. Lavanya
    • 1
  • Manjunatha M. Venkataswamy
    • 2
  • M. K. Sibin
    • 1
  • M. M. Srinivas Bharath
    • 3
  • G. K. Chetan
    • 1
  1. 1.Department of Human GeneticsNational Institute of Mental Health and Neuro SciencesBangaloreIndia
  2. 2.Department of NeurovirologyNational Institute of Mental Health and Neuro SciencesBangaloreIndia
  3. 3.Department of Neuro-chemistryNational Institute of Mental Health and Neuro SciencesBangaloreIndia

Personalised recommendations